Please cite this article in press B. Anish Babu et al, A Review On Current And Emerging Treatment Strategies Of Ulcerative Colitis., Indo Am. J. P. Sci, 2022; 09(3)

1. Abraham, C.; Cho, J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009, 361, 2066–2078. [CrossRef] [PubMed]
2. Silverberg, M.S.; Satsangi, J.; Ahmad, T.; Arnott, I.D.; Bernstein, C.N.; Brant, S.R.; Caprilli, R.; Colombel, J.-F.; Gasche, C.; Geboes, K.; et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 2005, 19 (Suppl. A), 5a–36a. [CrossRef] [PubMed]
3. Ungaro, R.; Mehandru, S.; Allen, P.B.; Peyrin-Biroulet, L.; Colombel, J.F. Ulcerative colitis. Lancet 2017, 389, 1756–1770. [CrossRef]
4. Cosnes, J.; Gower-Rousseau, C.; Seksik, P.; Cortot, A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011, 140, 1785–1794. [CrossRef] [PubMed]
5. Cohen, R.D.; Yu, A.P.; Wu, E.Q.; Xie, J.; Mulani, P.M.; Chao, J. Systematic review: The costs of ulcerative colitis in Western countries. Aliment. Pharmacol. Ther. 2010, 31, 693–707. [CrossRef]
6. Roda, G.; Narula, N.; Pinotti, R.; Skamnelos, A.; Katsanos, K.H.; Ungaro, R.; Burisch, J.; Torres, J.; Colombel, J.F. Systematic review with meta-analysis: Proximal disease extension in limited ulcerative colitis. Aliment. Pharmacol. Ther. 2017, 45, 1481–1492. [CrossRef]
7. Shah, S.C.; Colombel, J.F.; Sands, B.E.; Narula, N. Mucosal Healing Is Associated with Improved Long-term Outcomes of Patients with Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2016, 14, 1245–1255.e
8. [CrossRef] 8. Peyrin-Biroulet, L.; Sandborn, W.; Sands, B.E.; Reinisch, W.; Bemelman, W.; Bryant, R.V.; D’Haens, G.; Dotan, I.; Dubinsky, M.; Feagan, B.; et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am. J. Gastroenterol. 2015, 110, 1324–1338. [CrossRef] J. Clin. Med. 2020, 9, 94 9 of 12
9. Ko, C.W.; Singh, S.; Feuerstein, J.D.; Falck-Ytter, C.; Falck-Ytter, Y.; Cross, R. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019, 156, 748–764. [CrossRef]
10. Truelove, S.C.; Witts, L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br. Med. J. 1955, 2, 1041–1048. [CrossRef]
11. Schroeder, K.W.; Tremaine, W.J.; Ilstrup, D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987, 317, 1625–1629. [CrossRef] [PubMed]
12. Feagan, B.G.; Chande, N.; MacDonald, J.K. Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. Inflamm. Bowel Dis. 2013, 19, 2031–2040. [CrossRef] [PubMed]
13. Bressler, B.; Marshall, J.K.; Bernstein, C.N.; Bitton, A.; Jones, J.; Leontiadis, G.I.; Panaccione, R.; Steinhart, A.H.; Tse, F.; Feagan, B. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: The Toronto consensus. Gastroenterology 2015, 148, 1035–1058.e3. [CrossRef] [PubMed]
14. Lichtenstein, G.R.; Rutgeerts, P. Importance of mucosal healing in ulcerative colitis. Inflamm. Bowel Dis. 2010, 16, 338–346. [CrossRef] [PubMed]
15. Van Assche, G.; Manguso, F.; Zibellini, M.; CabriadaNuno, J.L.; Goldis, A.; Tkachenko, E.; Varoli, G.; Kleczkowski, D.; Annese, V.; D’Heygere, F.; et al. Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: Results from a double-blind, randomized, parallel group study. Am. J. Gastroenterol. 2015, 110, 708–715. [CrossRef]
16. Sandborn, W.J.; Danese, S.; D’Haens, G.; Moro, L.; Jones, R.; Bagin, R.; Huang, M.; David Ballard, E.; Masure, J.; Travis, S. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: Pooled analysis of two phase 3 studies. Aliment. Pharmacol. Ther. 2015, 41, 409–418. [CrossRef]
17. Danese, S.; Siegel, C.A.; Peyrin-Biroulet, L. Review article: Integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis. Aliment. Pharmacol. Ther. 2014, 39, 1095–1103. [CrossRef]
18. In Proceedings of the Abstracts from the 2014 Advances in Inflammatory Bowel Diseases Crohn’s & Colitis Foundation’s National Clinical & Research Conference, 4–6 December 2014, Orlando, FL, USA. Inflamm. Bowel Dis. 2014, 20 (Suppl. 1), S1–S124.
19. Kornbluth, A.; Sachar, D.B. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. 2010, 105, 501–523. quiz 524. [CrossRef]
20. Naganuma, M.; Aoyama, N.; Suzuki, Y.; Nishino, H.; Kobayashi, K.; Hirai, F.; Watanabe, K.; Hibi, T. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis. J. Crohns Colitis 2016, 10, 828–836. [CrossRef]
21. Sandborn, W.J.; Bosworth, B.; Zakko, S.; Gordon, G.L.; Clemmons, D.R.; Golden, P.L.; Rolleri, R.L.; Yu, J.; Barrett, A.C.; Bortey, E.; et al. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology 2015, 148, 740–750.e2. [CrossRef] [PubMed]
22. Hanauer, S.B.; Robinson, M.; Pruitt, R.; Lazenby, A.J.; Persson, T.; Nilsson, L.G.; Walton-Bowen, K.; Haskell, L.P.; Levine, J.G. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: A dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998, 115, 525–532. [CrossRef]
23. Gross, V.; Bar-Meir, S.; Lavy, A.; Mickisch, O.; Tulassay, Z.; Pronai, L.; Kupcinskas, L.; Kiudelis, G.; Pokrotnieks, J.; Kovacs, A.; et al. Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. Aliment. Pharmacol. Ther. 2006, 23, 303–312. [CrossRef] [PubMed]
24. Mulder, C.J.; Fockens, P.; Meijer, J.W.; van der Heide, H.; Wiltink, E.H.; Tytgat, G.N. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur. J. Gastroenterol. Hepatol. 1996, 8, 549–553. [CrossRef]
25. Jarnerot, G.; Hertervig, E.; Friis-Liby, I.; Blomquist, L.; Karlen, P.; Granno, C.; Vilien, M.; Strom, M.; Danielsson, A.; Verbaan, H.; et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study. Gastroenterology 2005, 128, 1805–1811. [CrossRef]
26. Rutgeerts, P.; Sandborn, W.J.; Feagan, B.G.; Reinisch, W.; Olson, A.; Johanns, J.; Travers, S.; Rachmilewitz, D.; Hanauer, S.B.; Lichtenstein, G.R.; et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2005, 353, 2462–2476. [CrossRef] J. Clin. Med. 2020, 9, 94 10 of 12
27. Reinisch, W.; Sandborn, W.J.; Hommes, D.W.; D’Haens, G.; Hanauer, S.; Schreiber, S.; Panaccione, R.; Fedorak, R.N.; Tighe, M.B.; Huang, B.; et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011, 60, 780–787. [CrossRef]
28. Sandborn, W.J.; Feagan, B.G.; Marano, C.; Zhang, H.; Strauss, R.; Johanns, J.; Adedokun, O.J.; Guzzo, C.; Colombel, J.F.; Reinisch, W.; et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146, 85–95. quiz e14–5. [CrossRef]
29. Sands, B.E.; Sandborn, W.J.; Panaccione, R.; O’Brien, C.D.; Zhang, H.; Johanns, J.; Adedokun, O.J.; Li, K.; Peyrin-Biroulet, L.; Van Assche, G.; et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2019, 381, 1201–1214. [CrossRef] 30. Feagan, B.G.; Rutgeerts, P.; Sands, B.E.; Hanauer, S.; Colombel, J.F.; Sandborn, W.J.; Van Assche, G.; Axler, J.; Kim, H.J.; Danese, S.; et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2013, 369, 699–710. [CrossRef]
31. Stidham, R.W.; Lee, T.C.; Higgins, P.D.; Deshpande, A.R.; Sussman, D.A.; Singal, A.G.; Elmunzer, B.J.; Saini, S.D.; Vijan, S.; Waljee, A.K. Systematic review with network meta-analysis: The efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 2014, 39, 660–671. [CrossRef] [PubMed]
32. Vasudevan, A.; Gibson, P.R.; van Langenberg, D.R. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J. Gastroenterol. 2017, 23, 6385–6402. [CrossRef] [PubMed] 33. Panaccione, R.; Ghosh, S.; Middleton, S.; Marquez, J.R.; Scott, B.B.; Flint, L.; van Hoogstraten, H.J.; Chen, A.C.; Zheng, H.; Danese, S.; et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014, 146, 392–400.e3. [CrossRef] [PubMed]
34. Singh, S.; Proudfoot, J.A.; Dulai, P.S.; Jairath, V.; Fumery, M.; Xu, R.; Feagan, B.G.; Sandborn, W.J. No Benefit of Concomitant 5-Aminosalicylates in Patients with Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am. J. Gastroenterol. 2018, 113, 1197–1205. [CrossRef]
35. Soler, D.; Chapman, T.; Yang, L.L.; Wyant, T.; Egan, R.; Fedyk, E.R. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 2009, 330, 864–875. [CrossRef]
36. Bickston, S.J.; Behm, B.W.; Tsoulis, D.J.; Cheng, J.; MacDonald, J.K.; Khanna, R.; Feagan, B.G. Vedolizumab for induction and maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2014, Cd007571. [CrossRef]
37. Sands, B.E.; Peyrin-Biroulet, L.; Loftus, E.V., Jr.; Danese, S.; Colombel, J.F.; Toruner, M.; Jonaitis, L.; Abhyankar, B.; Chen, J.; Rogers, R.; et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N. Engl. J. Med. 2019, 381, 1215–1226. [CrossRef]
38. Feagan, B.G.; Sandborn, W.J.; Gasink, C.; Jacobstein, D.; Lang, Y.; Friedman, J.R.; Blank, M.A.; Johanns, J.; Gao, L.L.; Miao, Y.; et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N. Engl. J. Med. 2016, 375, 1946–1960. [CrossRef]
39. Hanauer, S.; Panaccione, R.; Danese, S.; Cheifetz, A.; Reinisch, W.; Higgins, P.D.R.; Woodworth, D.A.; Zhang, H.; Friedman, G.S.; Lawendy, N.; et al. Tofacitinib Induction Therapy Reduces Symptoms within 3 Days for Patients with Ulcerative Colitis. Clin. Gastroenterol. Hepatol. 2019, 17, 139–147. [CrossRef]
40. Sandborn, W.J.; Ghosh, S.; Panes, J.; Vranic, I.; Su, C.; Rousell, S.; Niezychowski, W. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2017, 376, 1723–1736. [CrossRef] Cohen, D.; Grey, M.; Hilton, M.; Hutchings, H.; Morgan, J.; et al. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant tribute.